GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

Please provide your email address to receive an email when new articles are posted on . Spevigo (spesolimab) reduced the risk for generalized pustular psoriasis flares by 84% over 48 weeks. Spevigo’s ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...

Imsidolimab is a humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor. Treatment with imsidolimab led to significant clearance of pustulation, erythema, and scaling in ...

The US Food and Drug Administration (FDA) has approved spesolimab-sbzo, an interleukin (IL)-36 receptor antagonist, for the treatment of generalized pustular psoriasis (GPP) in adults and in pediatric ...

Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe form of ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven R. Feldman, ...

INGELHEIM, Germany--(BUSINESS WIRE)--Today, at the 25 th World Congress of Dermatology (WCD), Boehringer Ingelheim presented new late-breaking data from the EFFISAYIL™ 2 trial showing that spesolimab ...

If you’ve struggled with itchy, irritated skin, you’ve probably sought out various creams, lotions or ointments to treat it. But if you feel like you’ve tried everything and still suffer from dry and ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm Hawaii 2026 (Jan. 25-29), showcasing a comprehensive body of evidence across ...